TLCD3B and Gaucher disease: We therefore inhibited the glycoysphingolipids synthesis in vitro with eliglustat (Cerdelga®), an inhibitor of the ceramide synthase (IC50 = 24 nM) that is used for the treatment of pediatric patients with Niemann Pick’s and Gaucher’s disease [27].